These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30762807)

  • 41. Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Kozikowski M; Suarez-Ibarrola R; Osiecki R; Bilski K; Gratzke C; Shariat SF; Miernik A; Dobruch J
    Eur Urol Focus; 2022 May; 8(3):728-738. PubMed ID: 34099417
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monopolar versus bipolar transurethral resection of bladder tumors: An updated systematic review and meta-analysis of existing studies.
    Xu J; Zheng J; Ma Y
    Medicine (Baltimore); 2020 Aug; 99(34):e21768. PubMed ID: 32846804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of pirarubicin for nonmuscle invasive bladder cancer: A protocol of systematic review and meta-analysis.
    Chen DY; Cheng L; Dong LX; He WJ; Cao HF; Wang P; Yue CF
    Medicine (Baltimore); 2020 Jun; 99(23):e20415. PubMed ID: 32501988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
    Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
    Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review.
    He Y; Wang N; Zhou X; Wang J; Ding Z; Chen X; Deng Y
    BMJ Open; 2018 Apr; 8(4):e019635. PubMed ID: 29666128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.
    van den Bosch S; Alfred Witjes J
    Eur Urol; 2011 Sep; 60(3):493-500. PubMed ID: 21664041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
    BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of chromosome 7 aneuploidy measured by fluorescence in situ hybridization assay with muscular invasion in bladder cancer.
    Diao X; Cai J; Zheng J; Kong J; Wu S; Yu H; Huang H; Xie W; Chen X; Huang C; Huang L; Qin H; Huang J; Lin T
    Cancer Commun (Lond); 2020 Apr; 40(4):167-180. PubMed ID: 32279463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials.
    Yuan H; Qiu J; Liu L; Zheng S; Yang L; Liu Z; Pu C; Li J; Wei Q; Han P
    PLoS One; 2013; 8(9):e74142. PubMed ID: 24058522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Cumberbatch MGK; Foerster B; Catto JWF; Kamat AM; Kassouf W; Jubber I; Shariat SF; Sylvester RJ; Gontero P
    Eur Urol; 2018 Jun; 73(6):925-933. PubMed ID: 29523366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting Response to Intravesical Therapy in Non-muscle-invasive Bladder Cancer.
    Alameddine M; Kineish O; Ritch C
    Eur Urol Focus; 2018 Jul; 4(4):494-502. PubMed ID: 30098938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Shen P; Yang J; Wei W; Li Y; Li D; Zeng H; Wang J
    BJU Int; 2012 Sep; 110(6 Pt B):E209-15. PubMed ID: 22288379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
    Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S
    Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer.
    Fukushima H; Moriyama S; Waseda Y; Fukuda S; Uehara S; Tanaka H; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
    Eur Urol Focus; 2021 Mar; 7(2):366-372. PubMed ID: 31987764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC).
    Matsuyama H; Ikemoto K; Eguchi S; Oga A; Kawauchi S; Yamamoto Y; Kawai Y; Matsumoto H; Hara T; Nagao K; Sakano S; Sasaki K
    BJU Int; 2014 Apr; 113(4):662-7. PubMed ID: 23890221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.
    Xiong Y; Li J; Ma S; Ge J; Zhou L; Li D; Chen Q
    PLoS One; 2017; 12(2):e0170819. PubMed ID: 28192481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.